Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.In a preclinical trial, Introgen Therapeutics' investigational compound INGN 241 has been shown to work synergistically with Pfizer's Celebrex to inhibit the growth and increase apoptosis of breast cancer cells.
Subscribe to our email newsletter
These data demonstrate the potential utility of INGN 241 in combination with Celebrex, a drug approved for the treatment of precancerous lesions of the colon, and exemplify the increase in understanding of the effects of INGN 241 on multiple cancer-related pathways.
Results of this study may help in designing new low-toxicity treatment strategies that combat breast cancer.
Celebrex is approved by the FDA for the treatment of arthritis and is also approved as the first drug therapy for patients with familial adenomatous polyposis, a genetic condition that, if left untreated, almost invariably results in colon cancer.
“In this study, we demonstrate the synergistic activity between INGN 241 and celecoxib in killing breast cancer cells. Combining two low toxicity agents may provide additional options for breast cancer patients,” said Dr Sunil Chada, Introgen’s associate vice president of clinical research and an author on the paper.